EUVIMEDOpdag EUVIMED
Editorial

Recommendations from The Medical Education Editor

Mark Lavercombe iD

Respirology · 2024

DOI: 10.1111/resp.14640 ↗

At a glance

Editorial in Respirology, 2024. Written by Mark Lavercombe. Institution: Department of Respiratory & Sleep Disorders Medicine, Western Health, Melbourne, Victoria, Australia. Major MEDLINE topics: Asthma, Education, Medical. 12 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

benralizumab-and non-response was infrequent at 11.3% and 12.8%, respectively.Patients treated with benralizumab appeared to have a more significant reduction in exacerbation frequency and increase in FEV1 than those treated with mepolizumab.Although observational in nature, these data suggest the need for further investigation of potential differences between the anti-IL5 treatments.

Subjects

MeSH terms (MEDLINE)

AsthmaEducation, MedicalHumans

Author keywords

asthmaclinical teachingcontinued medical educationinterstitial lung diseaseprofessional developmentrespiratory function tests

Authors and institutions

  • Department of Respiratory & Sleep Disorders Medicine, Western Health, Melbourne, Victoria, Australia.
  • Department of Medical Education, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.

ORCID profiles: Mark Lavercombe

Cite

APA

Lavercombe, M. (2024). Recommendations from The Medical Education Editor. Respirology. https://doi.org/10.1111/resp.14640

Vancouver

Lavercombe M. Recommendations from The Medical Education Editor. Respirology. 2024. doi:10.1111/resp.14640

BibTeX
@article{Lavercombe2024,
  author = {Lavercombe, Mark},
  title = {Recommendations from The Medical Education Editor},
  journal = {Respirology},
  year = {2024},
  doi = {10.1111/resp.14640}
}
Start for free →